多位点联合抗感染治疗在慢性阻塞性肺疾病稳定期中的应用  

Application of multiple sites combined with anti-inflammatory therapy in stable stage of chronic obstruct pulmonary disease

作　　者：邵向荣[1] 胡涛[1] 杨德春[1] 王亚丽[1] 

机构地区：[1]江苏省扬州市第一人民医院呼吸内科,江苏扬州225000

出　　处：《实用临床医药杂志》2012年第17期133-134,137,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨多种作用位点的抗炎药物联合应用在慢性阻塞性肺疾病(COPD)稳定期中的临床疗效。方法将40例COPD稳定期患者随机分为2组,对照组吸入沙美特罗氟替卡松,治疗组在对照组基础上加用孟鲁司特钠、低剂量茶碱,治疗3个月后评价2组患者的肺功能、COPD评估测试(CAT)评分结果,并记录治疗期间2组患者急性加重例数和药物不良反应。结果治疗组的肺功能、CAT评分均较治疗前改善,且显著优于对照组。对照组急性加重例数虽大于治疗组,但差异无统计学意义,对照组未出现药物不良反应,治疗组药物不良反应轻微。结论在沙美特罗/氟替卡松吸入治疗基础上口服孟鲁司特、低剂量茶碱能进一步改善COPD稳定期患者的肺功能,提高生活质量。Objective To explore the clinical effect of multiple sites combined with anti-in- flammatory therapy in stable stage of chronic obstruct pulmonary disease （COPD）. Methods Forty COPD patients in stable stage were randomly divided into two groups. The control group inhaled salmeterol/fluticasone （50/500）. The treatment group inhaled salmeterol /fluticasone （50/500）, at the same time, jointing oral montelukasta and low dose theophylline. The pulmonary function, CAT scoring of the two groups, cases of AECOPD and the adverse reactions after three months were evaluated. Results After treatment, the pulmonary function and CAT score of the treatment group improved obviously, and also much better than that of the control group. There were more cases of AECOPD in the control group than in the treatment group, but there was no significant difference. There were no adverse drug reactions in the control group, and the adverse drug reactions of the treatment group were mild. Conclusion Inhaling salmeterol/fluticasone （50/500） and jointing oral montelukasta and low dose theophylline at the same time can improve lung function much better, improve life quality and reduce acute exacerbation.

关 键 词：孟鲁司特钠 低剂量茶碱 沙美特罗 氟替卡松 慢性阻塞性肺疾病 

分 类 号：R563[医药卫生—呼吸系统]